Literature DB >> 8960547

Anti-inflammatory 17beta-thioalkyl-16alpha,17alpha-ketal and -acetal androstanes: a new class of airway selective steroids for the treatment of asthma.

M J Ashton1, C Lawrence, J A Karlsson, K A Stuttle, C G Newton, B Y Vacher, S Webber, M J Withnall.   

Abstract

The synthesis and anti-inflammatory potencies of a new class of 17beta-thioalkyl-16alpha,17alpha-ketal and -acetal androstanes are described. This new class of steroids was made by fragmentation of 2-thioxo-1,2-dihydropyrid-1-yl esters of the corresponding 17-acids to the 17-radical. The radical generated was trapped using a variety of radicophilic disulfides, giving a steroidal D-ring having acetal or ketal functionality at C-16 and C-17, together with a sulfide link at C-17. Compounds from this series bind to the glucocorticoid receptor with high potency and are functional agonists as measured by their ability to induce tyrosine aminotransferase activity in a rat hepatic cell line in vitro. These 17beta-thioalkyl androstanes potently inhibit Sephadex-induced rat lung inflammation when administered directly into the airways. The high topical potency, together with a low propensity to induce systemic glucocorticoid-like side effects (rat thymus involution), provides the present compounds with a high degree of airway selectivity compared with currently available inhaled glucocorticoids. The presently described 17beta-thioalkyl-16alpha,17alpha-ketal androstanes may be useful for therapies for inflammatory diseases such as asthma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8960547     DOI: 10.1021/jm9604639

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  The maximal affinity of ligands.

Authors:  I D Kuntz; K Chen; K A Sharp; P A Kollman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Diastereoselective Synthesis of a Simplified Core of Rishirilide B.

Authors:  Lupe Mejorado; Thomas R R Pettus
Journal:  Synlett       Date:  2006-10-04       Impact factor: 2.454

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.